GlobeNewswire by notified

Low/no calorie sweeteners do not increase the risk of cardiovascular diseases

Share

ISA statement in response to new study by Debras, Chazelas et al.

BRUSSELS, Belgium, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The International Sweeteners Association (ISA) responds to the new study by Debras, Chazelas et al.1 on low/no calorie sweeteners and cardiovascular diseases highlighting that, contrary to claims made in this study, there is no causal evidence that low/no calorie sweeteners could increase the risk of cardiovascular diseases (CVDs).

Indeed, whilst the Debras, Chazelas et al study claim to show an association between low/no calorie sweeteners intake and CVD risk, there is no evidence of a plausible mechanism to support potential effects of low/no calorie sweeteners on cardiometabolic health.2The safety of all approved low/no calorie sweeteners has been confirmed by food safety bodies worldwide including the Joint Expert Committee on Food Additives of the United Nations Food and Agriculture Organization (FAO) and of the World Health Organization (WHO)3, the European Food Safety Authority (EFSA)4, and the US Food and Drug Administration (FDA)5.

Actually, the intake of low/no calorie sweeteners in the NutriNet-Santé cohort was extremely low, even for higher consumers (defined in the study as participants with sweetener intake above the sex specific median among consumers). Importantly, experts have questioned the ability to detect an association between low/no calorie sweeteners at such low levels of intake and any health outcome and stressed that, in such circumstances, confounding factors become more influential.6 By design, observational studies cannot establish a cause-and-effect relationship due to their observational nature and the inability to exclude residual confounding or, importantly, attenuate the effects of reverse causality.7

Contrary to the study by Debras, Chazelas et al, a systematic review and meta-analysis of prospective cohort studies including change and substitutions analyses that mitigate the influence of reverse causality providing more consistent and robust associations found that low/no calorie sweetened beverages are associated with lower risk of coronary heart disease and CVD mortality in the intended substitution for sugar-sweetened beverages.8 These findings are in line with evidence from randomised controlled trials which confirm no adverse effect of low/no calorie sweeteners on cardiometabolic risk factors including blood pressure, lipid levels, blood glucose and body weight, and in fact some benefits when used to replace sugars in the diet. 9,10

At a time when non-communicable diseases including diabetes and dental diseases remain major global health challenges, and in light of current public health recommendations to reduce overall sugar intake, low/no calorie sweeteners can be helpful in creating healthier food environments. They provide people with a wide choice of sweet-tasting options with low or no calories, and thus can be a useful tool, when used in place of sugar and as part of a balanced diet, in helping reduce overall sugar and calorie intake, as well as in managing blood glucose levels.11 Low/no calorie sweeteners are also not fermentable by oral bacteria, which means that they do not contribute to tooth demineralisation, which is one of the reasons for tooth decay.12

1 Debras C, Chazelas E, Sellem L, et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 2022;378:e071204.
2 Pyrogianni V, La Vecchia C. Letter by Pyrogianni and La Vecchia Regarding Article, “Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women’s Health Initiative”. Stroke. 2019 Jun;50(6):e169
3http://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/en/
4http://www.efsa.europa.eu/en/topics/topic/sweeteners
5https://www.fda.gov/food/food-additives-petitions/high-intensity-sweeteners
6 Magnuson B. Comments in response to the article by Debras et al “Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study”. Available at: https://journals.plos.org/plosmedicine/article/comment?id=10.1371/annotation/edab6e54-e06a-4e33-ba10-f1a96bc43152
7 La Vecchia C. Comments in response to the article by Debras et al “Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study”. Available at: https://journals.plos.org/plosmedicine/article/comment?id=10.1371/annotation/e28d577e-cd1c-42eb-85aa-7ea0cf0d5ccd
8 Lee JJ, Khan TA, McGlynn et al. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022 Aug 1;45(8):1917-1930
9 McGlynn ND, Khan TA, Wang L, et al. Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis. JAMA Network Open 2022 Mar 1;5(3):e222092
10 Rios-Leyvraz M, Montez J (World Health Organization)‎. Health effects of the use of non-sugar sweeteners: a systematic review and meta-analysis. World Health Organization (WHO) 2022. https://apps.who.int/iris/handle/10665/353064. License: CC BY-NC-SA 3.0 IGO
11 Diabetes UK. The use of low or no calorie sweeteners. Position Statement (Updated December 2018). Available at: https://www.diabetes.org.uk/professionals/position-statements-reports/food-nutrition-lifestyle/use-of-low-or-no-calorie-sweetners
12 EFSA Scientific opinion on the substantiation of health claims related to intense sweeteners. EFSA 2011 Journal 9(6): 2229, and 9(4): 2076

ISA - Avenue de Tervueren 13A – Bte 7, B-1040 Brussels, Belgium - Tel: +32 (0)2 736 53 54 - Fax: +32 (0)2 732 34 27
E-mail: info@sweeteners.org - Website: www.sweeteners.org - TVA BE 424.301.259

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye